Physician profile
Sandeep Kaur
NPI 1487956025
$1,726.07
in general payments reported to CMS, 2019-2025
18 companies · $297 in 2025
The $297 reported for 2025 was more than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $118 · 2021: $331 · 2022: $237 · 2023: $405 · 2024: $337 · 2025: $297.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,040.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,040.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $256.22 | 2022-2025 | Vyzulta, Miebo, Xiidra |
| Oyster Point Pharma, INC. | $209.15 | 2023-2025 | Tyrvaya, Ryzumvi, Ryzumvi |
| Abbvie INC. | $196.40 | 2022-2025 | |
| Aerie Pharmaceuticals, INC. | $180.82 | 2020-2021 | |
| Mallinckrodt Hospital Products INC. | $137.71 | 2022-2023 | Acthar |
| Tarsus Pharmaceuticals, INC. | $116.05 | 2024-2025 | Xdemvy |
| Sun Pharmaceutical Industries INC. | $115.29 | 2021-2024 | Cequa |
| Abiomed | $113.05 | 2021 | |
| Amgen INC. | $76.14 | 2024-2025 | Tepezza |
| Dompe US, INC. | $50.68 | 2022-2025 | Oxervate |
| Horizon Therapeutics Plc | $43.81 | 2022 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $37.03 | 2021 | |
| Harrow Eye, LLC | $34.81 | 2025 | Vevye |
| Alcon Vision LLC | $33.36 | 2025 | Eysuvis |
| Glaukos Corporation | $27.14 | 2021 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Rxsight INC | $24.65 | 2024 | Rxsight Injector Cartridge, Light Adjustable Lens (Lal), Rxsight Contact Lens |
| Kala Pharmaceuticals, INC. | $18.86 | 2021 | |
| Thea Pharma INC. | $18.25 | 2023 | Iyuzeh |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sandeep Kaur listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.